Explore our Knowledge Center!
Navigating Assay Validation in Cell Therapy
The submission process for Investigational Medicinal Product Dossier (IMPD) and Investigational New Drug (IND) applications in the context of cell therapies presents a range of challenges, from strict regulatory requirements to technical complexities in manufacturing and preclinical development. In this article, we explore the critical aspects of regulatory compliance, providing practical insights into navigating the process effectively. We outline best practices, including early regulatory discussions, alignment with international standards, and the importance of robust data management.
Navigating ASC Challenges: Expert Insights from Louis Casteilla
Adipose-derived stem cells (ASCs) a specialized subset of mesenchymal stem cells (MSCs), offer significant potential in regenerative medicine. These easily accessible cells, derived from adipose tissue, share many of the regenerative properties of MSCs, making them crucial in the development of innovative therapies. Their therapeutic applications are vast, with ongoing research focusing on improving their clinical use, optimizing production processes, and ensuring safety and efficacy. In this interview, Louis Casteilla, a leading expert on ASCs, discusses their potential in advancing medicine.
How to ensure a seamless IMPD/IND approval
The submission process for Investigational Medicinal Product Dossier (IMPD) and Investigational New Drug (IND) applications in the context of cell therapies presents a range of challenges, from strict regulatory requirements to technical complexities in manufacturing and preclinical development. In this article, we explore the critical aspects of regulatory compliance, providing practical insights into navigating the process effectively. We outline best practices, including early regulatory discussions, alignment with international standards, and the importance of robust data management.
The importance of the QTPP for Cell Therapy Developers
The Quality Target Product Profile (QTPP) serves as a strategic framework for guiding the development of cell therapies, ensuring alignment between clinical goals and regulatory requirements. This recommendation notice highlights the importance of establishing a well-defined QTPP early in the development process to mitigate risks and streamline regulatory approval. It provides practical guidelines for identifying critical quality attributes (CQAs) and offers insights into regulatory expectations specific to cell-based products. By adopting a proactive approach to QTPP, developers can enhance product quality, safety, and efficacy, while optimizing the pathway to market approval.
Contact
Tel : +33 534 276 550
Address : Cell-Easy SAS, 4 bis avenue Hubert Curien, 31100 Toulouse, France
Mail : info@cell-easy.com
